Lavipharm

Lavipharm is an integrated Group of companies engaged in the research, development, production, import, marketing, sales, and logistics services of pharmaceutical, dermocosmetic and healthcare products in Greece with a strong international activity. 

LAVIPHARM's plant is considered as one of the few in Greece with fully integrated production lines for solid and liquid pharmaceutical forms, transdermal delivery systems, epidermal cosmetic patches, creams and lotions. With operations throughout Greece, France, Cyprus and the United States of America, LAVIPHARM cooperates with well-known international pharmaceutical and cosmetic companies. Lavipharm Laboratories, LAVIPHARM's R&D arm in the U.S.A., spearheads both the development and marketing of its international products. The company's mission is to link innovative drug delivery discovery and product formulation technology with molecule transport, providing integrated development services from design phase to commercialisation. It achieves this with its unique solubilisation technologies and with a range of innovative delivery systems developed in - house. 

LAVIPHARM's first international product is a transdermal system that is smaller, thinner and esthetically superior to the ones already in the market. LAVIPHARM's once-a-day matrix transdermal patch of nitroglycerine for the treatment of angina is marketed in France, Italy, Belgium, Holland, Spain and Greece and since 2006 in Canada. 

LAVIPHARM has also entered into feasibility and/or development agreements with a number of companies in Europe and the U.S. for the development of products utilising its proprietary technology platforms. The pharmaceutical product most recently developed by Lavipharm Laboratories and already approved by the US Food & Drug Administration is a new generation generic fentanyl patch.